This is an observational study, aiming to investigate whether the ctDNA dynamics analyzed by the K-TrackTM assay could predict early response to Tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC). 1. Determine relationship between ctDNA dynamics and clinical response to TKI, * No response/progressive disease = ctDNA levels increase from baseline * Partial response/stable disease = ctDNA levels decrease from baseline * Complete response = ctDNA clearance. 2. Compare and combine ctDNA dynamics and RECIST1.1 to predict clinical response. 3. Determine relationship between ctDNA dynamics and progression free survival, overall survival.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Relationship between ctDNA dynamics and clinical response to TKI
Timeframe: 24 months following up.
To compare and combine ctDNA dynamics and RECIST1.1 to predict clinical response.
Timeframe: 24 months following up.
To investigate the relationship between ctDNA dynamics and progression free survival, overall survival.
Timeframe: 24 months following up.